21 July 2025
AOTI, INC. (the "Company" or "Group" or "AOTI")
California Medicaid Provider ID Awarded
By far the largest Medicaid state in US by enrolled population
Third state this year where the Company has been granted provider ID
Strong predicate reference site for CMS coverage and further states in commercial roll out
AOTI, INC. (AIM: AOTI), a medical technology group focused on the durable healing of wounds and the prevention of amputations, today announces further progress on its market access and commercial expansion strategy having successfully been granted a new Provider ID in California. This will allow the Company to start to secure insurers and obtain coverage for its TWO2 ® therapy in the state and support the Company's growth in the latter part of 2026.
California is by far the largest Medicaid state by enrolled population with 14.7 million, or 38%, of the population covered by Medi-Cal, California's specific Medicaid programme.1 This is the third state this year where the Company has been granted provider ID and is in line with its guidance of adding two to three states per year.
Medicaid has evolved to become the largest government funded healthcare program providing comprehensive coverage of health and long-term care to 83 million low-income people in the United States. Medicaid accounts for one-fifth of all US health care spending and covers one quarter of the entire population. Medicaid is jointly funded by states and the federal government but is uniquely administered by each state within broad federal rules.2
Dr. Mike Griffiths, Chief Executive Officer & President of AOTI, Inc., said:
"I am delighted we have been granted Provider ID in our home State of California, which is a significant milestone in our growth strategy and further validation of the unique value proposition we deliver. Securing market access in California is a major achievement and will allow us to begin to deliver the clinical and cost saving benefits of our TWO2 ® therapy to patients, providers and payors in the largest Medicaid market in the US, establishing a strong predicate reference site for CMS coverage where the process is already in progress and, for further states in the Company's commercial roll out."
2. https://www.kff.org/medicaid/issue-brief/10-things-to-know-about-medicaid/
ENDS
| AOTI, INC. Dr. Mike Griffiths, Chief Executive Officer Jayesh Pankhania, Chief Financial Officer
|
+44 (0)20 3727 1000 |
| Peel Hunt LLP (Nominated Adviser and Broker) Dr. Christopher Golden, James Steel
|
+44 (0)20 7418 8900 |
| FTI Consulting (Financial PR & IR) Ben Atwell, Simon Conway, Natalie Garland-Collins |
+44 (0)20 3727 1000 |
ABOUT AOTI, INC.
AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO2 ®) therapy has demonstrated in differentiating, robust, double-blinded randomized controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalizations and 71 per cent reduction in amputations over 12 months. TWO2 ® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO2 ® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. TWO2 ® therapy has also recently received positive recommendation from the Federal Joint Committee of Gemeinsamer Bundesausschuss (G-BA) in Germany. Also see www.aotinc.net
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.